These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 8578831)
21. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538 [TBL] [Abstract][Full Text] [Related]
22. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Kotloff KL; Herrington DA; Hale TL; Newland JW; Van De Verg L; Cogan JP; Snoy PJ; Sadoff JC; Formal SB; Levine MM Infect Immun; 1992 Jun; 60(6):2218-24. PubMed ID: 1587589 [TBL] [Abstract][Full Text] [Related]
23. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Mitra S; Chakrabarti MK; Koley H Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822 [TBL] [Abstract][Full Text] [Related]
24. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A; Sansonetti P Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655 [TBL] [Abstract][Full Text] [Related]
25. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735 [TBL] [Abstract][Full Text] [Related]
26. Novel self-sampling culture method to monitor excretion of live, oral Shigella flexneri 2a vaccine SC602 during a community-based phase 1 trial. Teska JD; Coster T; Byrne WR; Colbert JR; Taylor D; Venkatesan M; Hale TL J Lab Clin Med; 1999 Aug; 134(2):141-6. PubMed ID: 10444027 [TBL] [Abstract][Full Text] [Related]
27. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103 [TBL] [Abstract][Full Text] [Related]
28. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878 [TBL] [Abstract][Full Text] [Related]
29. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Wahid R; Simon JK; Picking WL; Kotloff KL; Levine MM; Sztein MB Clin Immunol; 2013 Jul; 148(1):35-43. PubMed ID: 23649043 [TBL] [Abstract][Full Text] [Related]
30. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Kärnell A; Cam PD; Verma N; Lindberg AA Vaccine; 1993; 11(8):830-6. PubMed ID: 8356844 [TBL] [Abstract][Full Text] [Related]
31. Protective milk O antibodies induced in guinea pigs by parenteral Shigella ribosomal vaccine. Chernokhvostova EV; Lyubinskaya MM; Belkin ZP; Levenson VI Int Arch Allergy Appl Immunol; 1990; 92(3):265-7. PubMed ID: 2276843 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616 [TBL] [Abstract][Full Text] [Related]
34. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. Black RE; Levine MM; Clements ML; Losonsky G; Herrington D; Berman S; Formal SB J Infect Dis; 1987 Jun; 155(6):1260-5. PubMed ID: 2437220 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
36. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes. Kärnell A; Sweiha H; Lindberg AA Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932 [TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378 [TBL] [Abstract][Full Text] [Related]
38. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. Levine MM; Woodward WE; Formal SB; Gemski P; DuPont HL; Hornick RB; Snyder MJ J Infect Dis; 1977 Oct; 136(4):577-82. PubMed ID: 333041 [TBL] [Abstract][Full Text] [Related]
39. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model. Yagnik B; Sharma D; Padh H; Desai P Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673 [TBL] [Abstract][Full Text] [Related]